Objective To analyz the eradication G17 and PG content changes and clinical significance of Hp eradication in patients with Hp related chronic stomach disease. Method 200 cases of healthy physical examination as control group, with 200 Hp correlation gastropathy patients as observation group, compared the levels of G17, PG Ⅰ , PG Ⅱ and PG Ⅰ /PG Ⅱ between the two groups. And compared the levels of G17, PG Ⅰ , PG Ⅱ and PG Ⅰ /PG Ⅱ and indigestion symptoms of different treatment effect and different types of two groups before and after treatment. Result The levels of G17, PG Ⅰ and PG Ⅱ of observation group were significantly higher than control group (P < 0.05), and PG Ⅰ /PG Ⅱ tatio was significantly lower than control group (P < 0.05). There were no obvious differences of G17, PG Ⅰ , PG Ⅱ and PG Ⅰ /PG Ⅱbefore and after treatment in observation group of Hp not eradicator (P > 0.05). After treatment, the levels of G17, PG Ⅰ and PG Ⅱ of Hp eradicator were significantly lower than before treatment and Hp not eradicator (P < 0.05), PG Ⅰ /PG Ⅱ ratio was significantly higher than Hp not eradicator (P < 0.05). There was no obvious difference of DSSI scores before treatment in Hp eradicator or not eradicator (P > 0.05), but in 1 month treatment, the DSSI score of Hp eradicator was significantly lower than Hp not eradicator (P < 0.05). There were obvious differences of G17, PG Ⅰ , PG Ⅱ and PG Ⅰ /PG Ⅱ among the three groups before and after treatment (P < 0.05), all at the highest of gastric polyps patients, with lowest of atrophic gastritis patients (P < 0.05). Conclusion The levels of serum G17 and PG are significantly increased in patients with Hp related gastric disease, The levels of serum G17 and PG are significantly improved after Hp eradication, they can be used as an effective index to evaluate the effect of Hp eradication.%目的：分析幽门螺杆菌（Hp）相关性胃病患者进行 Hp 根除后血清胃泌素17（G17）及胃蛋白酶原（PG）水平变化。方法以200例健康体检者为对照组，200例 Hp 相关性胃病患者为观察组，对比两组研究对象血清 G17、PG Ⅰ、PG Ⅱ水平及 PG Ⅰ/PG Ⅱ比值差异，并比较治疗效果及不同类型患者治疗前后血清 G17、PG Ⅰ、PG Ⅱ水平、消化不良症状变化情况及 PG Ⅰ/PG Ⅱ比值差异。结果观察组患者血清 G17、PG Ⅰ、PG Ⅱ水平均明显高于对照组（P ＜0.05），PG Ⅰ/PG Ⅱ比值明显低于对照组（P ＜0.05）。未根除组患者治疗前后血清 G17、PG Ⅰ、PG Ⅱ水平及 PG Ⅰ/PG Ⅱ比值比较差异均无显著性（P ＞0.05），根除组患者治疗后血清 G17、PG Ⅰ及 PG Ⅱ水平均明显低于治疗前及未根除组（P ＜0.05），PG Ⅰ/PG Ⅱ比值明显高于未根除组（P ＜0.05）。根除组与未根除组患者治疗前消化不良症状严重指数（DSSI）评分比较差异无显著性（P ＞0.05）；治疗后1个月，根除组患者 DSSI 评分明显低于治疗前及未根除组（P ＜0.05）。不同类型胃病患者治疗前后血清 G17、PG Ⅰ、PG Ⅱ水平差值及 PG Ⅰ/PG Ⅱ比值差值比较差异均具有显著性（P ＜0.05），均以胃息肉组最高，萎缩性胃炎组最低（P ＜0.05）。结论 Hp 相关性胃病患者血清 G17、PG 水平显著升高，而 Hp 根除后可显著改善患者血清 G17、PG 水平，临床可将血清 G17、PG 水平作为评价 Hp 根除效果的有效指标。
展开▼
